The impact of the envisia genomic classifier in the diagnosis and management of patients with idiopathic pulmonary fibrosis
Rationale: The diagnosis of idiopathic pulmonary fibrosis (IPF) remains challenging and can result in delayed or misdiagnosis. IPF diagnosis is based on the presence of either a radiographic or histologic usual interstitial pneumonia (UIP) pattern in the absence of an identifiable etiology. The Envi...
Saved in:
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
2022
|
| In: |
Annals of the American Thoracic Society
Year: 2022, Volume: 19, Issue: 6, Pages: 916-924 |
| ISSN: | 2325-6621 |
| DOI: | 10.1513/AnnalsATS.202107-897OC |
| Online Access: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1513/AnnalsATS.202107-897OC Verlag, lizenzpflichtig, Volltext: https://www.atsjournals.org/doi/10.1513/AnnalsATS.202107-897OC 
|
| Author Notes: | Joseph A. Lasky, Amy Case, Avraham Unterman, Michael Kreuter, Mary Beth Scholand, Sachin Chaudhary, Lori R. Lofaro, Marla Johnson, Jing Huang, Sangeeta M. Bhorade, Giulia C. Kennedy |
MARC
| LEADER | 00000caa a22000002c 4500 | ||
|---|---|---|---|
| 001 | 1837699534 | ||
| 003 | DE-627 | ||
| 005 | 20230706231720.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230228s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1513/AnnalsATS.202107-897OC |2 doi | |
| 035 | |a (DE-627)1837699534 | ||
| 035 | |a (DE-599)KXP1837699534 | ||
| 035 | |a (OCoLC)1389535150 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Lasky, Joseph |e VerfasserIn |0 (DE-588)128209582X |0 (DE-627)1837700249 |4 aut | |
| 245 | 1 | 4 | |a The impact of the envisia genomic classifier in the diagnosis and management of patients with idiopathic pulmonary fibrosis |c Joseph A. Lasky, Amy Case, Avraham Unterman, Michael Kreuter, Mary Beth Scholand, Sachin Chaudhary, Lori R. Lofaro, Marla Johnson, Jing Huang, Sangeeta M. Bhorade, Giulia C. Kennedy |
| 264 | 1 | |c 2022 | |
| 300 | |a 9 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 28.02.2023 | ||
| 520 | |a Rationale: The diagnosis of idiopathic pulmonary fibrosis (IPF) remains challenging and can result in delayed or misdiagnosis. IPF diagnosis is based on the presence of either a radiographic or histologic usual interstitial pneumonia (UIP) pattern in the absence of an identifiable etiology. The Envisia Genomic Classifier is a clinically validated molecular diagnostic test that identifies UIP in transbronchial biopsies. - - Objectives: To determine the impact of the Envisia Genomic Classifier on physicians’ clinical decision-making in the diagnosis and management of IPF. - - Methods: This prospective randomized decision impact survey was designed to test the hypothesis that including an Envisia UIP-positive result will increase IPF diagnoses, diagnostic confidence, and the recommendation for antifibrotic therapy. The survey included patients from the BRAVE (Bronchial Sample Collection for a Novel Genomic Test) study who had a high-resolution computed tomographic scan without a typical UIP pattern, an Envisia UIP-positive result, and a final diagnosis of IPF by multidisciplinary team discussion. Each case was presented in three different formats: a pre-post cohort, where each case is presented initially without and then with Envisia, and two independent cohorts, where each case is presented without and with Envisia, respectively. - - Results: U.S.-based pulmonologists from community and academic centers in geographically diverse practices were approached for inclusion in this study. 103 (65%) U.S.-based pulmonologists met the inclusion criteria and provided 605 case reviews of 11 patient cases. The number of IPF diagnoses increased with Envisia by an absolute difference of 39% from 47 (30%) before Envisia to 107 (69%) after Envisia in the pre-post cohort and by 13% in the independent cohorts. High confidence (⩾90%) of interstitial lung disease diagnoses was more commonly seen with Envisia in both the pre-post cohort and in the independent cohorts. Recommendation for antifibrotic treatment increased with Envisia by an absolute difference of 36% from 15 (10%) before Envisia to 72 (46.4%) after Envisia in the pre-post cohort and by 11% in the independent cohorts. - - Conclusions: This decision impact survey suggests the clinical utility of the Envisia Classifier by demonstrating a significant increase in IPF diagnoses, diagnostic confidence, and recommendation for antifibrotic therapies to assist physicians in effectively managing patients to improve outcomes of patients with IPF. | ||
| 650 | 4 | |a antifibrotic therapy | |
| 650 | 4 | |a interstitial lung disease | |
| 650 | 4 | |a surgical lung biopsy | |
| 650 | 4 | |a usual interstitial pneumonia | |
| 700 | 1 | |a Case, Amy |e VerfasserIn |4 aut | |
| 700 | 1 | |a Unterman, Avraham |e VerfasserIn |4 aut | |
| 700 | 1 | |a Kreuter, Michael |d 1972- |e VerfasserIn |0 (DE-588)122645995 |0 (DE-627)082066795 |0 (DE-576)293362742 |4 aut | |
| 700 | 1 | |a Scholand, Mary Beth |e VerfasserIn |4 aut | |
| 700 | 1 | |a Chaudhary, Sachin |e VerfasserIn |4 aut | |
| 700 | 1 | |a Lofaro, Lori R. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Johnson, Marla |e VerfasserIn |4 aut | |
| 700 | 1 | |a Huang, Jing |e VerfasserIn |4 aut | |
| 700 | 1 | |a Bhorade, Sangeeta M. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Kennedy, Giulia C. |e VerfasserIn |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |a American Thoracic Society |t Annals of the American Thoracic Society |d New York, NY : American Thoracic Society, 2013 |g 19(2022), 6, Seite 916-924 |h Online-Ressource |w (DE-627)736121897 |w (DE-600)2702474-X |w (DE-576)378731726 |x 2325-6621 |7 nnas |
| 773 | 1 | 8 | |g volume:19 |g year:2022 |g number:6 |g pages:916-924 |g extent:9 |a The impact of the envisia genomic classifier in the diagnosis and management of patients with idiopathic pulmonary fibrosis |
| 856 | 4 | 0 | |u https://doi.org/10.1513/AnnalsATS.202107-897OC |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u https://www.atsjournals.org/doi/10.1513/AnnalsATS.202107-897OC |x Verlag |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20230228 | ||
| 993 | |a Article | ||
| 994 | |a 2022 | ||
| 998 | |g 122645995 |a Kreuter, Michael |m 122645995:Kreuter, Michael |d 910000 |d 950000 |d 950900 |d 50000 |e 910000PK122645995 |e 950000PK122645995 |e 950900PK122645995 |e 50000PK122645995 |k 0/910000/ |k 1/910000/950000/ |k 2/910000/950000/950900/ |k 0/50000/ |p 4 | ||
| 999 | |a KXP-PPN1837699534 |e 4277676871 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"type":{"bibl":"article-journal","media":"Online-Ressource"},"recId":"1837699534","note":["Gesehen am 28.02.2023"],"language":["eng"],"person":[{"display":"Lasky, Joseph","role":"aut","roleDisplay":"VerfasserIn","given":"Joseph","family":"Lasky"},{"family":"Case","display":"Case, Amy","given":"Amy","role":"aut","roleDisplay":"VerfasserIn"},{"family":"Unterman","display":"Unterman, Avraham","given":"Avraham","roleDisplay":"VerfasserIn","role":"aut"},{"family":"Kreuter","given":"Michael","roleDisplay":"VerfasserIn","role":"aut","display":"Kreuter, Michael"},{"display":"Scholand, Mary Beth","role":"aut","roleDisplay":"VerfasserIn","given":"Mary Beth","family":"Scholand"},{"given":"Sachin","roleDisplay":"VerfasserIn","role":"aut","display":"Chaudhary, Sachin","family":"Chaudhary"},{"family":"Lofaro","given":"Lori R.","roleDisplay":"VerfasserIn","role":"aut","display":"Lofaro, Lori R."},{"role":"aut","roleDisplay":"VerfasserIn","given":"Marla","display":"Johnson, Marla","family":"Johnson"},{"family":"Huang","display":"Huang, Jing","role":"aut","roleDisplay":"VerfasserIn","given":"Jing"},{"family":"Bhorade","given":"Sangeeta M.","roleDisplay":"VerfasserIn","role":"aut","display":"Bhorade, Sangeeta M."},{"given":"Giulia C.","role":"aut","roleDisplay":"VerfasserIn","display":"Kennedy, Giulia C.","family":"Kennedy"}],"relHost":[{"note":["Gesehen 05.10.2018"],"part":{"pages":"916-924","extent":"9","year":"2022","text":"19(2022), 6, Seite 916-924","issue":"6","volume":"19"},"recId":"736121897","pubHistory":["10.2013 -"],"type":{"media":"Online-Ressource","bibl":"periodical"},"id":{"zdb":["2702474-X"],"eki":["736121897"],"issn":["2325-6621"]},"titleAlt":[{"title":"AnnalsATS"}],"corporate":[{"display":"American Thoracic Society","roleDisplay":"VerfasserIn","role":"aut"}],"title":[{"title":"Annals of the American Thoracic Society","title_sort":"Annals of the American Thoracic Society"}],"physDesc":[{"extent":"Online-Ressource"}],"origin":[{"dateIssuedDisp":"2013-","publisher":"American Thoracic Society","publisherPlace":"New York, NY","dateIssuedKey":"2013"}],"language":["eng"],"disp":"American Thoracic SocietyAnnals of the American Thoracic Society"}],"name":{"displayForm":["Joseph A. Lasky, Amy Case, Avraham Unterman, Michael Kreuter, Mary Beth Scholand, Sachin Chaudhary, Lori R. Lofaro, Marla Johnson, Jing Huang, Sangeeta M. Bhorade, Giulia C. Kennedy"]},"origin":[{"dateIssuedDisp":"2022","dateIssuedKey":"2022"}],"id":{"eki":["1837699534"],"doi":["10.1513/AnnalsATS.202107-897OC"]},"physDesc":[{"extent":"9 S."}],"title":[{"title":"The impact of the envisia genomic classifier in the diagnosis and management of patients with idiopathic pulmonary fibrosis","title_sort":"impact of the envisia genomic classifier in the diagnosis and management of patients with idiopathic pulmonary fibrosis"}]} | ||
| SRT | |a LASKYJOSEPIMPACTOFTH2022 | ||